Newest first

New topics page 21

Topics ordered by when they were created rather than by activity. This is where a question that nobody has answered yet is easiest to find — and answering one is the fastest route to a first solution badge.

1,535 topics · page 21 of 40

Topic	Participants	Replies	Views	Activity
External review after an internal denial Access › Insurance & coverage appeals prior authorisation insurance formulary Solved External review after an internal denial Writing it up because I had to work it out twice and would rather nobody else did. Proposing that external review deserves a maintained page rather than a recurring…		2	18k	1mo
What a good consultation looks like from the other side Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes beginner friendly What a good consultation looks like from the other side — that is the question, and I have not found it answered plainly anywhere I have looked. Something about good consultation does not reconcile and I…	+57	62	4.9k	22h
Packaging that arrived damaged: documenting it properly — a second dataset Sourcing › Logistics customs shipping temperature excursion Posting this under the heading it deserves: Packaging that arrived damaged: documenting it properly — a second dataset Everything below is what sits behind that. A logistics question, since the answers here…	+68	73	20k	4mo
[2026 update] Why mass spectrometry cannot tell you about an epimer Analytics › Mass spectrometry high-resolution MS counter-ion content MALDI-TOF Why mass spectrometry cannot tell you about an epimer — that is the question, and I have not found it answered plainly anywhere I have looked. Working through the identity arithmetic and I would like it…		2	1k	8mo
[2026 update] How much of the diluent volume the powder itself displaces Practice › Reconstitution reconstitution worked example syringe units Wiki Closed The question in the title: How much of the diluent volume the powder itself displaces I will give what I have already checked below so nobody repeats it. Writing this out with the numbers in it, because…	+89	100	3.2k	8mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…	+100	108	1.3k	8mo
Reading U-100 graduations, with a conversion table Devices › Syringes & needles dead volume worked example subcutaneous injection needle gauge & length Posting this under the heading it deserves: Reading U-100 graduations, with a conversion table Everything below is what sits behind that. A question about reading U-100 graduations that I think has a definite…	+35	41	2k	1d
Coming back to: Pen dose counters: what a click does and does not guarantee Devices › Pens & autoinjectors storage subcutaneous injection dead volume Pen dose counters: what a click does and does not guarantee — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about Pen dose counters, three…		4	105	5mo
Coming back to: "Greater than or equal to 99%" as a specification rather than a result Analytics › COA interpretation documentation quality amino acid analysis certificate of analysis batch & lot numbers Posting this under the heading it deserves: "Greater than or equal to 99%" as a specification rather than a result Everything below is what sits behind that. Two reports on the same lot, and I would like help…		2	31k	6mo
Coming back to: Injection-site reactions: describing them precisely enough to be useful Practice › Side effects hair shedding fatigue constipation nausea On the subject in the title: Injection-site reactions: describing them precisely enough to be useful Working notes rather than a conclusion. Reading back through what has been written here about…	+21	25	22k	8mo
Gastro-oesophageal reflux: improving or worsening? Clinical › Comorbidities PCOS obstructive sleep apnoea MASH / hepatic steatosis chronic kidney disease Solved The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Collecting what is known about gastro-oesophageal reflux in…	+54	58	8.2k	1mo
[2026 update] Reporting a disappointing outcome, and why it belongs here Outcomes › Progress reports DXA long read data table Pinned Closed On the subject in the title: Reporting a disappointing outcome, and why it belongs here Working notes rather than a conclusion. Proposing that Reporting a disappointing outcome deserves a maintained page…		2	11k	8mo
Availability by country, dated, with primary sources — one year on Access › International personal import MHRA NHS Availability by country, dated, with primary sources — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…	+7	11	850	7mo
[2026 update] Comparing prices across jurisdictions without misleading yourself Access › Pricing formulary compounding data table On the subject in the title: Comparing prices across jurisdictions without misleading yourself Working notes rather than a conclusion. Comparing prices across jurisdictions keeps being re-asked here and I…		2	809	23h
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide effect size type 2 diabetes semaglutide STEP programme Solved The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…	+23	27	9.9k	1mo
Lurking for two months before posting: was that the right call? Start Here › Welcome guidelines trust levels beginner friendly Asking directly, because I could not find a straight answer: Lurking for two months before posting: was that the right call? Question in the title. Context below, and I have tried to include the things people…	+66	71	11k	8mo
Heterogeneity as information rather than as a nuisance Evidence › Meta-analyses heterogeneity risk of bias meta-analysis effect size Posting this under the heading it deserves: Heterogeneity as information rather than as a nuisance Everything below is what sits behind that. An honest uncertainty about heterogeneity rather than a disguised…	+88	95	1.2k	6mo
Second pass at: A reconstituted vial's beyond-use date and the reasoning behind common figures Practice › Storage & stability beyond-use date cold chain temperature excursion freeze-thaw Solved Second pass at: A reconstituted vial's beyond-use date and the reasoning behind common figures Writing it up because I had to work it out twice and would rather nobody else did. Something changed and I would…	+4	8	20k	8mo
DXA precision and the least significant change for lean mass Outcomes › Body composition bioimpedance data table DXA Closed Posting this under the heading it deserves: DXA precision and the least significant change for lean mass Everything below is what sits behind that. A question about measurement precision rather than about…	+81	85	2.7k	7mo
Robustness: the parameters worth deliberately varying Analytics › Method validation stability-indicating method linearity precision & repeatability Robustness: the parameters worth deliberately varying Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about robustness, deliberately narrow, because the…	+53	57	664	8mo
A 40-week log with the measurement method stated — does this still hold? Outcomes › Progress reports effect size DXA data table Solved A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on 40-week log. It is…	+1	5	14k	2mo
LOD and LOQ: definitions people get wrong Analytics › Method validation precision & repeatability recovery stability-indicating method linearity Closed LOD and LOQ: definitions people get wrong — setting out what I have, and where I think it stops being reliable. What changes if the standard account of LOD and LOQ is wrong? I ask because I have been treating…		2	43k	8mo
Pen dose counters: what a click does and does not guarantee Devices › Pens & autoinjectors missed dose subcutaneous injection storage Under review On the subject in the title: Pen dose counters: what a click does and does not guarantee Working notes rather than a conclusion. Pen dose counters — I have the observation and I do not trust my interpretation…	+116	122	1.6k	8mo
Revisiting: Aggregates and why a purity assay may miss them entirely Analytics › Impurities & related substances endotoxin testing HPLC counter-ion content water content Solved Posting this under the heading it deserves: Revisiting: Aggregates and why a purity assay may miss them entirely Everything below is what sits behind that. I would like to disagree carefully with the settled…	+48	53	918	8mo
Second pass at: The topic list is dense — is that deliberate? Meta › Site feedback site feedback moderation guidelines Solved Second pass at: The topic list is dense — is that deliberate? I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on topic list. It is mine, it is…	+101	108	8.4k	4mo
Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide SURPASS programme randomised trial effect size tirzepatide Wiki On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…	+18	29	20k	8mo
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide type 2 diabetes randomised trial semaglutide SELECT trial Solved Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…	+5	9	30k	8d
Cardiovascular risk: reading the outcome trials as a set Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease type 2 diabetes obstructive sleep apnoea Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Reading back through what has been written here about cardiovascular…		4	12k	5mo
Reused chromatograms across lots: how to spot it — what changed since Analytics › COA interpretation batch & lot numbers amino acid analysis reference standards documentation quality Solved Reused chromatograms across lots: how to spot it — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Reused chromatograms across…	+34	39	20k	2mo
CJC-1295 with and without DAC: what the modification does — what changed since Compounds › Secretagogues & GH axis GHRP class observational data CJC-1295 tesamorelin CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of…		4	5.1k	7mo